USPTO Examiner GIBBS TERRA C - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19258035OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSIONJuly 2025December 2025Allow500NoNo
18886396APOPTOTIC CELL MIMICSeptember 2024April 2025Allow710YesNo
18797746BIOMARKER FOR PREDICTING DRUG RESISTANCE OF BRUTON'S TYROSINE KINASE INHIBITORS AND APPLICATION THEREOFAugust 2024January 2025Allow510NoNo
18794874Enzymatic RNA Capping MethodAugust 2024October 2025Allow1541NoNo
18634158USE OF PI3KC2B INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITYApril 2024September 2025Abandon1701NoNo
18633108HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWALApril 2024August 2025Allow1610NoNo
18608025APOPTOTIC CELL MIMICMarch 2024August 2024Allow511YesNo
18606312CONTROL OF INSECT INFESTATIONMarch 2024September 2025Allow1810NoNo
18598943SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGETMarch 2024February 2026Abandon2420NoNo
18587710CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAFebruary 2024February 2026Allow2421YesNo
18433225METHOD FOR QUANTIFYING AN AMOUNT OF CAPPED MESSENGER RNAFebruary 2024October 2025Allow2030NoNo
18529152COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFDecember 2023November 2025Allow2411NoNo
18524302METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASENovember 2023July 2025Abandon1901NoNo
18507183FACTOR XII (F12) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2023February 2024Allow400NoNo
18493610COMPOSITIONS FOR MODULATING ATAXIN 2 EXPRESSIONOctober 2023November 2025Allow2510NoNo
18491513OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSIONOctober 2023August 2025Allow2220YesNo
18487302KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2023March 2025Allow1710NoNo
18368620RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)September 2023October 2025Abandon2501YesNo
18465077Loop-Mediated Synthetic RiboregulatorsSeptember 2023September 2025Allow2411NoNo
18239189SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENTAugust 2023April 2025Abandon2010NoNo
18234952METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)August 2023April 2025Abandon2010NoNo
18231434KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFAugust 2023January 2025Abandon1701NoNo
18218638COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)July 2023October 2025Abandon2710NoNo
18218155FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) IRNA COMPOSITIONS AND METHODS OF USE THEREOFJuly 2023February 2025Allow2011NoNo
18215848KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2023January 2025Abandon1810NoNo
18334932RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of UseJune 2023December 2023Allow610NoNo
18300937COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITYApril 2023March 2026Allow3510NoNo
18131509METHODS OF TREATING OSMIDROSISApril 2023December 2024Abandon2010NoNo
18191623CONDITIONAL-SIRNAS AND USES THEREOF IN TREATING ACUTE MYELOID LEUKEMIAMarch 2023March 2026Allow3521YesNo
18026388TREATMENT OF OPTIC ATROPHYMarch 2023January 2026Allow3410NoNo
18181057CONJUGATES AND PREPARATION AND USE THEREOFMarch 2023March 2026Abandon3611NoNo
18180179COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOFMarch 2023March 2025Abandon2411NoNo
18116903COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENEMarch 2023November 2024Abandon2001NoNo
18043051COMB SHAPED ANTIVIRALS ENDING WITH OR WITHOUT CHAIN TERMINATING BASESFebruary 2023November 2025Allow3310NoNo
18172707OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSIONFebruary 2023November 2024Allow2111NoNo
18150381MODULATION OF FACTOR 11 EXPRESSIONJanuary 2023May 2025Abandon2810NoNo
18088395C/EBP Alpha Short Activating RNA Compositions and Methods of UseDecember 2022May 2025Abandon2820NoNo
18069123COMPOSITIONS AND METHODS FOR PREPARING CAPPED MRNADecember 2022October 2023Allow1020YesNo
18080954DEFIBROTIDE FOR THE PREVENTION AND TREATMENT OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY ASSOCIATED WITH IMMUNODEPLETIONDecember 2022September 2025Allow3421YesNo
18064086Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisDecember 2022August 2023Allow820YesNo
18063972Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisDecember 2022August 2023Allow830YesNo
18062422OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOFDecember 2022January 2026Allow3721NoNo
18060990KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFDecember 2022July 2023Allow710YesNo
18071424METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF LDHANovember 2022May 2025Abandon3020NoNo
18056929REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOFNovember 2022January 2025Abandon2610NoNo
18055597USE OF PI3KC2B INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITYNovember 2022August 2024Abandon2111NoNo
17987064METHODS FOR TREATING HYPERCHOLESTEROLEMIANovember 2022December 2024Abandon2510NoNo
18049378GAMMA HERPESVIRUS CIRCULAR RNAOctober 2022December 2024Abandon2621NoNo
17963962METHOD FOR ENHANCING RECOVERY OF COSMETIC LASER-TREATED SKINOctober 2022November 2024Abandon2510NoNo
17907741ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2022September 2025Allow3601NoNo
17936258HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2022August 2024Allow2210NoNo
17931270HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWALSeptember 2022January 2024Allow1610NoNo
17929950COMPOSITIONS AND METHODS FOR INHIBITING ASAH1 GENE EXPRESSIONSeptember 2022January 2026Abandon4010NoNo
17900921KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2022January 2026Abandon4110NoNo
17802905FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE SKIN GRAFT HEALINGAugust 2022December 2025Abandon4010NoNo
17893742IN VITRO TRANSCRIPTION TECHNOLOGIESAugust 2022January 2025Allow2920YesNo
17817303NOVEL PRECURSOR MIRNA AND APPLICATION THEREOF IN TUMOR TREATMENTAugust 2022September 2024Abandon2501NoNo
17816087MICRORNA ASSAY FOR DETECTION AND MANAGEMENT OF PANCREATIC CANCER PRECURSORSJuly 2022June 2024Allow2320NoNo
17813493p63 INACTIVATION FOR THE TREATMENT OF HEART FAILUREJuly 2022February 2024Allow1910NoNo
17867260siRNA-Copolymer Compositions And Methods Of Use For Treatment Of Liver CancerJuly 2022August 2024Abandon2510NoNo
17865156TOPICAL COMPOSITION COMPRISING RETINOL AND PDRN AND USE OF SAMEJuly 2022July 2025Allow3610YesNo
17855851ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJuly 2022August 2024Abandon2511NoNo
17843162METHOD FOR PREPARING MRNA-GALNAC TARGETING MOLECULE, IN VIVO DELIVERY SYSTEM THEREFOR, AND USE THEREOFJune 2022March 2024Abandon2121YesNo
17786344Template-Free Enzymatic Polynucleotide Synthesis Using Dismutationless Terminal Deoxynucleotidyl Transferase VariantsJune 2022November 2025Abandon4101NoNo
17834762METHODS AND COMPOSITIONS FOR DETECTING AND TREATING ENDOMETRIOSISJune 2022March 2023Abandon901NoNo
17782797INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIESJune 2022March 2026Abandon4511NoNo
17778366ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOFMay 2022October 2025Allow4111NoNo
17777792ANTISENSE OLIGONUCLEOTIDES AND THIER USE FOR THE TREATMENT OF CANCERMay 2022October 2025Abandon4110YesNo
17776399ANTISENSE OLIGONUCLEOTIDE SEQUENCES FOR SILENCING THE HUMAN L1-MET TRANSCRIPT IN TUMORSMay 2022July 2025Allow3910NoNo
17740066METHODS AND COMPOSITIONS FOR MODULATING ALPHA-1-ANTITRYPSIN EXPRESSIONMay 2022January 2024Abandon2010NoNo
17661803SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGETMay 2022November 2023Allow1810NoNo
17731766RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of UseApril 2022February 2026Allow4511NoNo
17731317HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFApril 2022January 2026Allow4511NoNo
17723555COMPOSITIONS AND METHODS FOR DISRUPTING THE MOLECULAR MECHANISMS ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION AND NEURODEGENERATIVE DISEASEApril 2022February 2024Allow2221NoNo
17721666METHODS AND COMPOSITIONS FOR TREATING ATHEROSCLEROSISApril 2022March 2025Abandon3540NoNo
17714730Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses ThereofApril 2022May 2025Abandon3720NoYes
17714717Materials And Methods Of Treating MHC-1-Opathy Risk HaplotypesApril 2022March 2025Allow3621NoNo
17712766Selective Antisense Compounds and Uses ThereofApril 2022January 2024Abandon2110NoNo
17766153CHEMICAL MODIFICATIONS OF SMALL INTERFERING RNA WITH MINIMAL FLUORINE CONTENTApril 2022April 2025Allow3600NoNo
17700339METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASEMarch 2022February 2024Abandon2301NoNo
17697685MODIFIED iRNA AGENTSMarch 2022September 2024Abandon3011NoNo
17696510INHIBITING APE2 EXPRESSION IN A SUBJECT TREATED WITH A DRUG AGENT THAT CAUSES INCREASED APE2 EXPRESSIONMarch 2022July 2025Allow4052NoNo
17586850PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2022May 2025Allow4021YesNo
17584463TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASESJanuary 2022March 2024Allow2610NoNo
17581089OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSIONJanuary 2022August 2023Allow1910NoNo
17575410METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAsJanuary 2022August 2024Allow3130NoNo
17626775VARIANT REVERSE TRANSCRIPTASE EXHIBITING EXCELLENT STABILITYJanuary 2022January 2026Abandon4820NoNo
17554920COMPOUNDS AND METHODS FOR MODULATING FACTOR XIIDecember 2021December 2023Allow2402NoNo
17554476MICRORNA ASSAY FOR DETECTION AND MANAGEMENT OF PANCREATIC CANCER PRECURSORSDecember 2021June 2025Allow4141YesNo
17615413OLIGONUCLEOTIDE THERAPY FOR WOLMAN DISEASE AND CHOLESTERYL ESTER STORAGE DISEASENovember 2021August 2025Abandon4501NoNo
17453950ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALINGNovember 2021January 2024Abandon2611NoNo
17517006ANTISENSE NUCLEIC ACIDSNovember 2021March 2024Allow2911NoNo
17502816Large Scale Synthesis of Messenger RNAOctober 2021December 2025Allow5041YesYes
17602765GENETIC AMPLIFIED TUMOR HOMING NANOPARTICLES AND COMPOSITIONS AND METHODS THEREOFOctober 2021January 2026Allow5121YesNo
17494039SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENTOctober 2021October 2023Abandon2410NoNo
17494751STABILIZED POLYRIBONUCLEOTIDE CODING FOR AN ELASTIC FIBROUS PROTEINOctober 2021March 2025Allow4140NoYes
17487019METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)September 2021October 2023Abandon2410NoNo
17472413CONTROL OF INSECT INFESTATIONSeptember 2021November 2023Allow2611NoNo
17464871KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOFSeptember 2021August 2023Abandon2301NoNo
17402081DOUBLE-STRANDED OLIGO RNA STRUCTURE COMPRISING miRNAAugust 2021November 2023Abandon2710NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GIBBS, TERRA C.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
6
Examiner Affirmed
5
(83.3%)
Examiner Reversed
1
(16.7%)
Reversal Percentile
27.6%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
80
Allowed After Appeal Filing
15
(18.8%)
Not Allowed After Appeal Filing
65
(81.2%)
Filing Benefit Percentile
23.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GIBBS, TERRA C - Prosecution Strategy Guide

Executive Summary

Examiner GIBBS, TERRA C works in Art Unit 1635 and has examined 915 patent applications in our dataset. With an allowance rate of 51.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.

Allowance Patterns

Examiner GIBBS, TERRA C's allowance rate of 51.6% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GIBBS, TERRA C receive 1.90 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GIBBS, TERRA C is 31 months. This places the examiner in the 54% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +25.7% benefit to allowance rate for applications examined by GIBBS, TERRA C. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 21.2% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.5% of cases where such amendments are filed. This entry rate is in the 65% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.4% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 73.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.9% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.9% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.0% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.